Suraksha Diagnostics IPO: Public Issue Sees Tepid Subscription On Day 1, GMP Flat; Check Key Dates & More

The Suraksha Diagnostics IPO, a mainboard offering by one of India's leading diagnostic service providers, has seen a lukewarm response since its opening on November 29, 2024. The IPO, aiming to raise Rs 846.25 crore through a complete offer-for-sale (OFS) of 1.92 crore shares, is set to close on December 3, 2024. Despite its strong market presence and extensive network in East India, investor interest on the first day was subdued, with just 11% subscription recorded.

The public issue reserved 50% of shares for qualified institutional buyers (QIBs), 15% for non-institutional investors (NIIs), and 35% for retail investors. By the end of Day 1, the QIB portion remained unsubscribed, while NIIs booked only 0.04% of their reserved shares. Retail investors accounted for 2% of the total shares, with 14.62 lakh applications received against an offering of 1.34 crore shares. Interestingly, the IPO's grey market premium (GMP) stood at Re 0, indicating shares were trading at their issue price of Rs 441 without any premium or discount, signalling a cautious stance among investors.

IPO Details

Suraksha Diagnostics has set its price band at Rs 420 to Rs 441 per share, with a minimum lot size of 34 shares. The IPO is entirely an OFS, with proceeds directed to selling shareholders, including the promoters and investors such as OrbiMed Asia II Mauritius Limited and the Kejriwal family. The offer aims to transfer up to 19,189,330 equity shares, while its objectives include facilitating the sale and gaining the benefits of listing on NSE and BSE.

ICICI Securities, Nuvama Wealth Management, and SBI Capital Markets are the book-running lead managers, and Kfin Technologies is the registrar. Following the closure of subscriptions, the allotment of shares will be finalized on December 4, with refunds and share crediting to demat accounts slated for December 5. The shares are expected to be listed on December 6.

Suraksha Diagnostics has demonstrated robust growth, recording a 14.75% increase in revenue and an extraordinary 281.32% rise in profit after tax between FY23 and FY24. The company operates a central reference lab, eight satellite labs, and 215 customer touchpoints, including 49 diagnostic centres and 166 sample collection centres, primarily in West Bengal, Bihar, Assam, and Meghalaya. These centres serve as a hub-and-spoke model, enhancing operational efficiency and turnaround time.

Peer Comparison
Operating in a competitive diagnostic sector, Suraksha Diagnostics faces industry heavyweights such as Dr Lal PathLabs, Metropolis Healthcare, Thyrocare, and Vijaya Diagnostic. With price-to-earnings (P/E) ratios of 77.08, 89.61, 65.52, and 86.40, respectively, these peers set a high benchmark for market performance. Suraksha Diagnostics' growth trajectory places it in a favourable position, but the current subdued GMP and Day 1 subscription figures highlight investor caution amidst broader market volatility.

The firm's focus on East India, accounting for 95.34% of its operational revenue, is a double-edged sword. While it underscores strong regional dominance, it also raises concerns about geographical concentration. The company's hub-and-spoke model, however, provides scalability, enabling it to expand its services and improve operational efficiencies. In Q1 FY25 alone, it conducted 1.58 million tests for approximately 2,80,000 patients.

Suraksha Diagnostics' IPO launch coincides with a bustling IPO season on Dalal Street, featuring eight listings and three ongoing IPOs this week. However, global uncertainties, including geopolitical tensions and fluctuating macroeconomic indicators, seem to have tempered investor enthusiasm. Despite the muted start, the upcoming days of subscription could see improved traction as retail and institutional investors assess the company's strong financial performance and growth potential.